1. Influenza C virus in U.S. children with acute respiratory infection 2016-2019.
- Author
-
Sederdahl BK, Weinberg GA, Campbell AP, Selvarangan R, Schuster JE, Lively JY, Olson SM, Boom JA, Piedra PA, Halasa NB, Stewart L, Szilagyi PG, Balasubramani GK, Sax T, Martin JM, Hickey RW, Michaels MG, and Williams JV
- Subjects
- Humans, Child, Preschool, Male, Infant, Female, United States epidemiology, Child, Adolescent, Coinfection virology, Coinfection epidemiology, Acute Disease epidemiology, Influenza, Human epidemiology, Influenza, Human virology, Respiratory Tract Infections virology, Respiratory Tract Infections epidemiology, Gammainfluenzavirus isolation & purification, Gammainfluenzavirus genetics
- Abstract
Influenza C virus (ICV) is an orthomyxovirus related to influenza A and B, yet due to few commercial assays, epidemiologic studies may underestimate incidence of ICV infection and disease. We describe the epidemiology and characteristics of ICV within the New Vaccine Surveillance Network (NVSN), a Centers for Disease Control and Prevention (CDC)-led network that conducts population-based surveillance for pediatric acute respiratory illness (ARI). Nasal or/combined throat swabs were collected from emergency department (ED) or inpatient ARI cases, or healthy controls, between 12/05/2016-10/31/2019 and tested by molecular assays for ICV and other respiratory viruses. Parent surveys and chart review were used to analyze demographic and clinical characteristics of ICV+ children. Among 19,321 children tested for ICV, 115/17,668 (0.7 %) ARI cases and 8/1653 (0.5 %) healthy controls tested ICV+. Median age of ICV+ patients was 18 months and 88 (71.5 %) were ≤36 months. Among ICV+ ARI patients, 40 % (46/115) were enrolled in the ED, 60 % (69/115) were inpatients, with 15 admitted to intensive care. Most ICV+ ARI patients had fever (67.8 %), cough (94.8 %), or wheezing (60.9 %). Most (60.9 %) ARI cases had ≥1 co-detected viruses including rhinovirus, RSV, and adenovirus. In summary, ICV detection was rarely associated with ARI in children, and most ICV+ patients were ≤3 years old with co-detected respiratory viruses., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr Weinberg reported reports honoraria from Merck & Co for writing and revising textbook chapters. Dr Weinberg has served on an Scientific Advisory Board for Inhalon Biopharma. Dr Selvarangan reported receiving grants from Merck & Co, Inc, BioFire, Luminex, Hologic, Abbott, Becton Dickinson, and Cepheid outside the submitted work. Dr Halasa reported receiving grants from Sanofi and Quidel as well as personal fees from Genentech outside the submitted work. Dr Szilagyi reported receiving grants from the University of California, Los Angeles David Geffen School of Medicine BROAD Program during the conduct of the study. Dr Sahni reported receiving grants for her institution from the Centers for Disease Control and Prevention (CDC) outside the submitted work. Dr Martin reported receiving funding from Merck, Sharp and Dohme outside the submitted work. Dr. Williams reported receiving grants from the NIH outside the submitted work. No other conflicts were reported., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF